Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study - PubMed
4 days ago
- #Risankizumab
- #real-world outcomes
- #Crohn's disease
- The study assessed the effectiveness and safety of Risankizumab (RZB) in a real-world cohort of Crohn's disease (CD) patients.
- 520 patients were included, with 45.0% having failed ≥3 prior treatments and 54.8% previously exposed to ustekinumab.
- At week 12, 76.5% showed clinical response, and 60.8% achieved steroid-free clinical remission (SFCR).
- By week 52, SFCR was 65.6%, endoscopic remission was 37.5%, radiologic remission was 24.6%, and transmural healing was 9.8%.
- Ustekinumab-naïve patients had better early clinical outcomes and higher endoscopic remission rates compared to ustekinumab-exposed patients.
- Effectiveness at week 52 was similar between patients with 2 and ≥3 prior treatment failures.
- Extra-intestinal manifestations decreased over time, while perianal disease showed modest improvement.
- Risankizumab was well-tolerated with no new safety signals identified.
- The study concluded that RZB is effective for refractory CD, with similar outcomes regardless of prior treatment failures.